TCER AB is a privately held biopharmaceutical company based in Stockholm, Sweden.

TCER conducts its research in close cooperation with the research group Therapeutic Immune Design at the Centre for Molecular Medicine at Karolinska Institute. The company is focussing their efforts to develop personalized immunotherapy for cancer and multiple sclerosis using their unique clinical network and proprietary technology.